
|Videos|December 13, 2019
The monarcHER Trial in Advanced HR+, HER2+ Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, discusses the results of the monarcHER trial, which examined adding the CDK4/6 inhibitor abemaciclib and endocrine therapy to trastuzumab versus trastuzumab plus chemotherapy in advanced hormone receptor-positive, HER2-positive breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
2
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
3
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
4
Lurbinectedin and Tarlatamab in ES-SCLC
5








































